Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Infect Dis. 2010 Dec;23(6):609-16. doi: 10.1097/QCO.0b013e3283402956.

Advances in Chagas disease drug development: 2009-2010.

Author information

1
Department of Medicine, Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, 98195, USA. fbuckner@u.washington.edu

Abstract

PURPOSE OF REVIEW:

The need for better drugs to treat patients with Chagas disease remains urgent. This review summarizes the advancements in drug development over the past 2 years.

RECENT FINDINGS:

Drug development efforts are almost exclusively occurring as preclinical research, although phase II studies for the antifungal drug, posaconazole, and a prodrug of ravuconazole are being planned. Several recent laboratory investigations demonstrate anti-Trypanosoma cruzi activity of novel small molecules in animal models. These include nonpeptidic cruzain inhibitors, novel inhibitors of the sterol 14α-demethylase enzyme, new compounds (arylimidamides) related to pentamidine, derivatives of nifurtimox, compounds using ruthenium complexes, and several natural products. The recent implementation of a high-throughput screen of more than 300 000 compounds against intracellular T. cruzi amastigotes done at the Broad Institute is an important development, yielding approximately 300 selective inhibitors, many of which may serve as leads for medicinal chemistry efforts.

SUMMARY:

Progress is slow, but recent advancements in both drug development and advocacy for research on neglected diseases are encouraging. Efforts to define a target product profile and to harmonize methodologies for testing drugs for Chagas disease are described herein.

PMID:
20885320
PMCID:
PMC3603362
DOI:
10.1097/QCO.0b013e3283402956
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer Icon for PubMed Central
    Loading ...
    Support Center